PAST DATA RESULTS

Past Data

Ticker Date Current phase Disease Area Market cap Trial outcome Ticker Prob 1 Ticker Prob 2 Phase Prob Disease Prob MC Prob Quarter
ITEK 08/19/2017 3 Opthalmology $240M fail 43.80% 40.9 Quarter
AGRX 08/19/2017 3 other $143.73m fail 48% 47.5 Quarter
OTIC 08/19/2017 3 Infectious disease $489.15M success 54.60% 51.85 Quarter
TENX 08/19/2017 3 Other $65.24M fail 42% 47.5 Quarter
ANTH 08/19/2017 3 Autoimmune $89.3m Fail 46.20% 34.1 Quarter
OPHT 08/19/2017 3 Ophthalmology $1.3B fail 51.60% 52.6 Quarter
NOVN 08/19/2017 3 Skin infections $305m fail 1/27 55% 51.75 Quarter
CATB 08/19/2017 2 other $75.1M fail 33.30% 31.9 9.9 22 Quarter
TRVN 08/19/2017 3 other $372M success 52.8 50.75 Quarter
AVIR 08/19/2017 2 infections disease $48.69M fail 35.7 33.55 9.9 23.65 0 Quarter
AXON 08/19/2017 2 Dementia $1.22B 16.8 11.7 Quarter
NDRM 08/19/2017 2 Neurology $600.73m Success 28.8 29.4 Quarter
CELG 08/19/2017 3 Multiples Scerosis (Other) 94B Success 59.2 9 38.5 11.7 Quarter
CDTX 08/19/2017 2 Infection $195.08M fail 35.4 33.55 Quarter
CYCC 08/19/2017 3 Other $22M fail 51 47.5 Quarter
BCRX 08/19/2017 2 -- $406.21M Quarter
LJPC 08/19/2017 3 Cardiovascular 332.59M Success* 41.95 Quarter
ACOR 08/19/2017 3 Neurology/Parkinson's dz $943M Success 52.05 Quarter
PTCT 08/19/2017 3 Other $448.54M fail 50.2 Quarter
AUPH 08/19/2017 2 Autoimmune $196.65m Success 27.5 Quarter
KPTI 08/19/2017 2 Other $570.81M fail 31.9 Quarter
TGTX 08/19/2017 3 Other $292.81M Success* 47.5 Quarter
IONS 08/19/2017 3 Other $6.10B Success 59.2 Quarter
NKTR 08/19/2017 3 Other (Opiod) $2.37B Success 59.2 Quarter
CRBP 08/19/2017 2 Cystic Fibrosis (Other) $462.67M 34.6 Quarter
GNMX 2 Other $219.99M fail 31.9 Quarter
LLY 3 Other (Breast Cancer) $88.38B Success 59.2 Quarter
RARE 2 Other (Seizure) $3.27b FAIL 43.6 Quarter
XENE 2 Other (facial acne) 176.67M fail 31.9 Quarter
FOMX 3 All indications $338.23M FAIL 44.5 Quarter
VRTX 3 Other (Cystic Fibrosis) $22.28B Success 55.7 Quarter
PRTK 3 Infections disease $495.86M Success 51.85 Quarter
NVCR 3 Oncology $713.52M Success 33.7 Quarter
OMED 2 Oncology $327.61M Fail 26.35 Quarter
RARE 3 Other $2.50B Success 59.2 Quarter
NTRP 2 Alzheimer's $147.43M Fail 9.9 Quarter
AEZS 3 Other $49.93M Fail 48.4 Quarter
ITEK 2 Opthalmology 46.55M Fail 33.75 Quarter
ZYNE 2 Others $200M 31.9 Quarter

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.